Question 1

What is Zalsupindole?

Accepted Answer

Zalsupindole is a Other.

Question 2

How often does Zalsupindole appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Zalsupindole first tracked by Ergen?

Accepted Answer

First tracked on May 28, 2026.

Question 4

When was Zalsupindole last mentioned in news?

Accepted Answer

Last active on May 28, 2026.

Question 5

What is Zalsupindole's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Zalsupindole in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Zalsupindole?

Accepted Answer

Delix Zalsupindole Phase 1b Results (May 28, 2026, 6 articles).

Question 8

How did the "Delix Zalsupindole Phase 1b Results" event impact Zalsupindole?

Accepted Answer

Zalsupindole (DLX-001), a novel neuroplastogen developed by Delix Therapeutics, showed promising Phase 1b results, indicating no cognitive impairment and supporting at-home administration, which could accelerate its development for Major Depressive Disorder.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.